PDCD1 and clear cell renal carcinoma: <h4>Background</h4>Programmed cell death 1 (PD-1) or PD-ligand 1 (PD-L1) blocker-based strategies have improved the survival outcomes of clear cell renal cell carcinomas (ccRCCs) in recent years, but only a small number of patients have benefited from them.<h4>Methods</h4>In this study, we developed a multi-omics machine learning model based on inflammatory and immune signatures (TIs) to predict the response and survival of ccRCC patients to immune checkpoint blockade (ICB) therapy.